Mathematical models of targeted cancer therapy
Open Access
- 10 October 2006
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 95 (9) , 1136-1141
- https://doi.org/10.1038/sj.bjc.6603310
Abstract
Improved understanding of the molecular underpinnings of cancer initiation and progression has led to the development of targeted cancer therapies. The importance of these new methods of cancer treatment necessitates further research into the dynamic interactions between cancer cells and therapeutic agents, as well as a means of analysing their relationship quantitatively. The present review outlines the application of mathematical modelling to the dynamics of targeted cancer therapy, focusing particular attention on chronic myeloid leukaemia and its treatment with imatinib (Glivec).Keywords
This publication has 35 references indexed in Scilit:
- Evolution of Resistance During Clonal ExpansionGenetics, 2006
- Dynamics of chronic myeloid leukaemiaNature, 2005
- Drug resistance in cancer: Principles of emergence and preventionProceedings of the National Academy of Sciences, 2005
- Targeted cancer therapyNature, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- The Hallmarks of CancerCell, 2000
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999